Innovative Can-C Eye Drops

Formulated by a bio-physicist and a Russian research team in the early 1990’s, Can-C eye drops are a viable option to cataract surgery.   In a human trial on cataract sufferers over a six month period 88.9 per cent had improved glare sensitivity.  90 per cent reported improved visual acuity and 41 per cent experienced significant improvement in lens ‘transmissivity’.  This refers to the clouding of the eye lens.

What are Can-C eye drops?  It is a formulation of the anti-oxidant carnosine known as n-acetylcarnosine (NAC).   NAC ‘mops up’ free radicals which are the root of tissue damage and the culprit behind cataract formation.  Carnosine is capable of addressing the process of glycation which is where glucose leads to hardening of tissues over time.  Can-C eye drops are a powerful antioxidant boost to the eyes resulting in a protection of the eye lens proteins from free-radical induced deterioration.

If left alone, cataracts lead to sight loss and eventual blindness.  28,000 new cases are reported every day which is a staggering number.  In the February issue I discussed nutritional options to slow down or possibly reverse the formation of cataracts such as Protandim, hyaluronic acid, liposomal vitamin C, Vitamin E and omega-3 fatty acids.  Lutein is beneficial but is not recommended if taking Can-C eye drops.  Lutein will slow down the benefits of taking Can-C.

Recommended dosage of Can-C eye drops is two drops, twice a day.  A slight stinging in the eye may occur for a few seconds.  Measurable effects are often seen within 1 month of use but a period of 3 to 5 months is recommended for best results.

Can-C is packaged as an eye lubricant because it is not approved by the FDA as a drug to treat cataracts.  Besides an eye lubricant it may also be helpful for eye strain, ocular inflammation, blurred vision, dry eye, corneal disorders and retinal diseases.

Ask an associate in our Natural Living department to purchase Can-C or to ask questions.

 

Leave a Reply

Your email address will not be published.